Medical students as adverse drug event managers, learning about side effects while improving their reporting in clinical practice

Managing adverse drug reactions (ADRs) is a problem, particularly as a result of most healthcare professionals are insufficiently educated for this process. Since context-based clinical pharmacovigilance coaching has confirmed efficient, we assessed the feasibility and impact of a making a crew of Junior-Adverse Drug Event Managers (J-ADEMs). The J-ADEM crew consisted of medical students (1st-Sixth 12 months) tasked with managing and reporting ADRs in hospitalized sufferers. Feasibility was evaluated utilizing questionnaires. Student competence in reporting ADRs was evaluated utilizing a case-control design and questionnaires earlier than and after J-ADEM program participation.
From Augustus 2018 to Augustus 2019, 41 students participated in a J-ADEM crew and screened 136 sufferers and submitted 65 ADRs experiences to the Netherlands Pharmacovigilance Center Lareb. Almost all sufferers (n = 61) discovered it vital that “their” ADR was reported, and all (n = 62) sufferers felt they had been taken critically by the J-ADEM crew. Although attending physicians agreed that the ADRs ought to have been reported, they didn’t achieve this themselves primarily due to a “lack of awareness and attitudes” (50%) and “excuses made by healthcare professionals” (49%). J-ADEM crew students had been considerably extra competent than management students in managing ADRs and accurately making use of all steps for diagnosing ADRs (management group 38.5% vs. intervention group 83.3%, p < 0.001).
The J-ADEM crew is a possible method for detecting and managing ADRs in hospital. Patients had been happy with the care supplied, physicians had been supported in their ADR reporting obligations, and students acquired related fundamental and clinical pharmacovigilance abilities and information, making it a win-win-win intervention. A 3-h workshop, aimed to critically appraise analysis papers, reviewed cervical and ovarian most cancers screening strategies. The workshop was facilitated by a Consultant in Gynae-oncology Surgery. Anonymous analysis was requested from 200 9 students attending through the 2018/2019 educational 12 months. Qualitative analysis with thematic evaluation of content material was carried out.
One hundred fifty-six students gave analysis on the workshop itself (74.6%). Three important themes had been identified-support for the significance of instructing screening strategies, appreciation of the significance of understanding cervical screening and a want for additional instructing in Critical Appraisal. Students recognized that there was a necessity to know screening, that it was “..vital for us to think about the worth of screening programmes”. The instructing on Cervical screening was “..useful, particularly with cervical screening”.

Initial Resuscitation of a Multisystem Trauma Patient Following a Fall From Height: A Complete Simulation Scenario for Medical Students

Management of a fancy trauma affected person is a crucial talent for medical students, significantly throughout a common surgical procedure or emergency medication clerkship. However, gaining proficiency with this skillset could also be difficult with out prior medical or simulation expertise. The purpose of this technical report is to current a complete high-fidelity medical simulation of a polytraumatized affected person with quite a few accidents sustained from a 20-foot fall.

As the situation unfolds, students determine multisystem accidents together with acute hemorrhage, femur fracture, pressure pneumothorax, and traumatic mind harm. The case was designed as an evaluation device to guage the information of preclinical medical students obtained by way of a one-day workshop on the first survey. This technical report supplies simulation designers with a premade script, flowchart, labs, pictures, and provides wanted to efficiently recreate the case.

Medical students as adverse drug event managers, learning about side effects while improving their reporting in clinical practice

Medical Student Ultrasound Education: The Radiology Chair Weighs In

To assess the radiology division chairs’ opinions regarding present standing and plans for instructing ultrasound to medical students, the American College Taskforce on Radiology Ultrasound Education, commissioned by the American College of Radiology, distributed a survey to 142 radiology chairs and a medical college dean subgroup.The response price was 30% (42/142), and 76% indicated ultrasound was presently a part of the medical pupil curriculum. In preclinical years, radiology involvement was solely 6.4%. During clinical years, radiology led ultrasound schooling with 51.7% in common and 82.9% in elective rotations.

Regarding precise content material, prime Four outcomes had been evenly distributed between learning hands-on scanning (81.1%), diagnostic use of ultrasound (75.7%), anatomy/pathology (75.7%), and ultrasound steerage for procedures (54.0%). Educational leaders in preclinical programs had been emergency medication (72.7%) adopted by radiology (45.4%) physicians. During clinical years, leaders had been radiology (52.6%) and emergency medication (47.4%) physicians.

Most chairs said that information of diagnostic ultrasound ought to be necessary (76.2%), stressing the significance of instructing the diagnostic capabilities and makes use of of ultrasound as the first purpose (78.8%). Perceived boundaries to implementation had been evenly distributed between lack of area in the curriculum (55.6%), lack of college (48.2%), lack of assets (44.4%), and lack of institutional help (40.7%). The American College Taskforce on Radiology Ultrasound Education survey exhibits that radiology’s position in ultrasound undergraduate schooling happens nearly completely throughout clinical years, and the chairs voice a want to enhance upon this position. Barriers embrace each intradepartmental (college and assets) and institutional (curricular) elements.

For medical faculties, the COVID-19 pandemic necessitated examination and curricular restructuring as effectively as vital adjustments to clinical attachments. With the obtainable proof suggesting that medical students’ psychological well being standing is already poorer than that of the final inhabitants, with educational stress being a chief predictor, such adjustments are more likely to have a major impact on these students.

transferrin fragment
A1093-1 1 mg
EUR 108
Description: Transferrin is the principal ironbinding protein in animal serum and is analogous in its iron-binding site and properties to lactoferrin1. Human transferrin is a single-chain glycoprotein of molecular weight near 80,000.

Thrombin Sepharose Beads
7925-1
EUR 218

Pannexin 1 Fragment (4515) Peptide
20-abx266300
  • EUR 495.00
  • EUR 815.00
  • EUR 356.00
  • 10 mg
  • 25 mg
  • 5 mg

Pannexin 1 Fragment (4512) Peptide
20-abx266362
  • EUR 523.00
  • EUR 871.00
  • EUR 384.00
  • 10 mg
  • 25 mg
  • 5 mg

Anti-PAR1/Thrombin Receptor/F2R Antibody
A03352-1 100ug/vial
EUR 334

Thrombin Human Recombinant Protein
PROTP00734-1 Regular: 20ug
EUR 317
Description: Thrombin Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 296 amino acids (328-622) and having a molecular mass of 33.9 kDa.

Rac GTPase fragment
A1086-1 1 mg
EUR 108
Description: Rac GTPase fragment, (C46H74N12O14), a peptide with the sequence H2N-Val-Phe-Asp-Glu-Ala-Ile-Arg-Ala-Val-OH, MW= 1019.15. Rac is a subfamily of the Rho family of GTPases, small signaling G proteins (more specifically a GTPase).

Thrombin Receptor Agonist Peptide
A8668-10 10 mg
EUR 1118
Description: Agonist at the thrombin receptor; causes platelet aggregation (EC50 = 4 ?M) and secretion.

Thrombin Receptor Agonist Peptide
A8668-5 5 mg
EUR 651
Description: Agonist at the thrombin receptor; causes platelet aggregation (EC50 = 4 ?M) and secretion.

Thrombin Receptor Agonist Peptide
A8668-5.1 10 mM (in 1mL DMSO)
EUR 2267
Description: Agonist at the thrombin receptor; causes platelet aggregation (EC50 = 4 ?M) and secretion.

Thrombin Receptor Blocking Peptide
AF0263-BP 1mg
EUR 195

Trypsinogen Activation Peptide (TAP) Antibody
20-abx103074
  • EUR 398.00
  • EUR 133.00
  • EUR 1107.00
  • EUR 537.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Trypsinogen Activation Peptide (TAP) Antibody
20-abx174951
  • EUR 787.00
  • EUR 411.00
  • 1 mg
  • 200 ug

Human Thrombin AssayMax ELISA Kit
ET4010-1 96 Well Plate
EUR 417

PKC fragment (530-558)
B5213-1 1 mg
EUR 297

Influenza A virus fragment
A1075-1 1 mg
EUR 96
Description: Influenza A virus fragment has the RNA sequence of Leu-Lys-Phe-Ala-Phe-Ser-Met-Met.Influenzavirus A is agenusof the Orthomyxoviridaefamily of viruses.

p53 tumor suppressor fragment
A1083-1 1 mg
EUR 108
Description: p53 tumor suppressor fragment (232-240),(C41H67N11O14S4), a peptide with the sequence H2N-Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met-OH, MW= 1066.3. p53 (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that in humans is encoded by the TP53 gene(1).

type II collagen fragment
A1096-1 1 mg
EUR 108
Description: Type II collagen is composed of a triple helix of three identical ? chains. These molecules associate to form a fibril that is stabilized by intermolecular crosslinks1.

coagulation factor II (thrombin) B chain fragment [Homo sapiens]
A1057-10 10 mg
EUR 340
Description: Thrombin (H2N-Lys-Pro-Val-Ala-Phe-Ser-Asp-Tyr-Ile-His-Pro-Val-Cys-Leu-Pro-Asp-Arg-OH) is a "trypsin-like" serine protease that is encoded by the F2 gene in humans. [1] Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa).

coagulation factor II (thrombin) B chain fragment [Homo sapiens]
A1057-25 25 mg
EUR 456
Description: Thrombin (H2N-Lys-Pro-Val-Ala-Phe-Ser-Asp-Tyr-Ile-His-Pro-Val-Cys-Leu-Pro-Asp-Arg-OH) is a "trypsin-like" serine protease that is encoded by the F2 gene in humans. [1] Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa).

coagulation factor II (thrombin) B chain fragment [Homo sapiens]
A1057-5 5 mg
EUR 224
Description: Thrombin (H2N-Lys-Pro-Val-Ala-Phe-Ser-Asp-Tyr-Ile-His-Pro-Val-Cys-Leu-Pro-Asp-Arg-OH) is a "trypsin-like" serine protease that is encoded by the F2 gene in humans. [1] Thrombin is produced by the enzymatic cleavage of two sites on prothrombin by activated Factor X (Xa).

Collagen Binding Fragment Peptide
20-abx266190
  • EUR 439.00
  • EUR 718.00
  • EUR 328.00
  • 10 mg
  • 25 mg
  • 5 mg

P75 TNFR Fragment Peptide
20-abx266292
  • EUR 495.00
  • EUR 815.00
  • EUR 356.00
  • 10 mg
  • 25 mg
  • 5 mg

HIV-gp41-Fragment Peptide
20-abx265740
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Scrambled TRAP Fragment Peptide
20-abx265858
  • EUR 356.00
  • EUR 537.00
  • EUR 286.00
  • 10 mg
  • 25 mg
  • 5 mg

Gastric Juice Peptide Fragment
H-2074.0500 0.5mg
EUR 113
Description: Sum Formula: C62H98N16O22; CAS# [137525-51-0]

Gastric Juice Peptide Fragment
H-2074.1000 1.0mg
EUR 171
Description: Sum Formula: C62H98N16O22; CAS# [137525-51-0]

EZAct? Procathepsin Activation Buffer
1030-1
EUR 153

Thrombin Antibody
abx022382-05mg 0.5 mg
EUR 1156

Thrombin Antibody
abx022419-100ug 100 ug
EUR 425

Thrombin Antibody
6685-100
EUR 338

Thrombin Antibody
6685-30T
EUR 146

Thrombin antibody
20R-1363 10 mg
EUR 281
Description: Sheep polyclonal Thrombin antibody

Thrombin antibody
20R-1364 10 mg
EUR 247
Description: Sheep polyclonal Thrombin antibody

Thrombin antibody
20R-1372 10 mg
EUR 281
Description: Sheep polyclonal Thrombin antibody

Thrombin antibody
70R-10615 500 ug
EUR 529
Description: Affinity purified sheep polyclonal Thrombin antibody

Thrombin antibody
70R-10617 500 ug
EUR 541
Description: Affinity purified sheep polyclonal Thrombin antibody

Thrombin antibody
70R-TS001 500 ug
EUR 529
Description: Affinity purified sheep polyclonal Thrombin antibody

Anti-Thrombin III Blocking Peptide
20-abx161017
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg

Thrombin, Active, Bovine Plasma (Technical grade)
7591-1
EUR 120

Thrombin, Active, Bovine Plasma (High Activity)
7592-1
EUR 158

Anti-Fibroblast activation protein, alpha/FAP Antibody
A00422-1 100ug/vial
EUR 294

Thrombin inhibitor 1
HY-U00370 1mg
EUR 2337

Rac1 Activation Assay
STA-401-1 20 assays
EUR 757
Description: Our Rac Activation Assays use visible agarose beads to selectively precipitate the active form of Rac1 or Rac2. The precipitated small GTPase is then detected by Western blot using a Rac1- or Rac2-specific antibody included in the kit.

Arf1 Activation Assay
STA-407-1 20 assays
EUR 757
Description: Our Arf Activation Assays use visible agarose beads to selectively precipitate the active form of Arf1 or Arf 6. The precipitated small GTPase is then detected by Western blot using an Arf1- or Arf6-specific antibody included in the kit.

Prothrombin fragment 1 antibody
70R-10602 500 ug
EUR 492
Description: Affinity purified sheep polyclonal Prothrombin fragment 1 antibody

Cytochrome c fragment (93-108)
A1062-1 1 mg
EUR 137
Description: H2N-ANERADLIAYLKQATK-OHTheCytochrome cis a smallhemeproteinfound loosely associated with the inner membrane of themitochondrion. Cytochromes c from certain eukaryotes, including plants and fungi but not higher animals, contains methylated lysine residues at specific positions1.

MAP kinase fragment [Multiple species]
A1079-1 1 mg
EUR 108
Description: This Mitogen-activated protein kinase (MAP kinase) fragment has a peptide sequence of Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu.The MAP kinases are serine/threonine-specific protein kinasesbelonging to the CMGC (CDK/MAPK/GSK3/CLK) kinase group.

ubiquitin specific protease 3 fragment
A1097-1 1 mg
EUR 108
Description: The ubiquitin speci?c protease 3 USP3 is a deubiquitinating enzyme for uH2A and uH2B. USP3 dynamically associates with chromatin and deubiquitinates H2A/H2B in vivo.

Cytokeratin Fragment Antigen 21-1 Peptide (OVA)
20-abx165524
  • EUR 578.00
  • EUR 258.00
  • EUR 1720.00
  • EUR 690.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Trypsinogen Activation Peptide (TAP) Antibody (Biotin)
20-abx272518
  • EUR 425.00
  • EUR 230.00
  • EUR 1191.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

GTP-Binding Protein Fragment, G alpha
A1022-1 1 mg
EUR 90
Description: Sequence: Cys-Gly-Ala-Gly-Glu-Ser-Gly-Lys-Ser-Thr-Ile-Val-Lys-Gln-Met-LysUsing specific antisera raised against synthetic peptides, we find that three distinct GTP-binding protein alpha subunits remain bound to the plasma membrane even after activation with nonhydrolyzable GTP analog.

amyloid A protein fragment [Homo sapiens]
A1053-1 1 mg
EUR 108
Description: Amyloid A proteins (H2N-Ala-Gly-Leu-Pro-Glu-Lys-Tyr-OH), also called Serum amyloid A (SSA) proteins, are a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma.

ferritin heavy chain fragment [Multiple species]
A1069-1 1 mg
EUR 108
Description: Sequence: H2N-YLNEQVKAI-OHThe two heavy chains are colored red and blue and the two light chains green and yellow.Ferritin is a protein of 450 kDa consisting of 24 subunits that is present in every cell type.

PKA inhibitor fragment (6-22) amide
A1117-1 1 mg
EUR 131
Description: Ki: 1.6 nMPKA inhibitor fragment (6-22) amide is a PKA inhibitor. In cell biology, protein kinase A (PKA) is a family of enzymes whose activity is dependent on cellular levels of cyclic AMP (cAMP). PKA is also regarded as a cAMP-dependent protein kinase.

Human beta-Amyloid 25-35 fragment
BAM2535-1 1 mg
EUR 408

Rap1 Activation Assay Kit
STA-406-1 20 assays
EUR 757
Description: Our Rap Activation Assays use visible agarose beads to selectively precipitate the active form of Rap1 or Rap2. The precipitated small GTPase is then detected by Western blot using a Rap1- or Rap2-specific antibody included in the kit.

Thrombin
HY-114164 500ug
EUR 119

Human Thrombin Antibody
11571-05011 150 ug
EUR 217

Human Thrombin Antibody
35147-05111 150 ug
EUR 261

Polyclonal Thrombin Antibody
APR10458G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Thrombin . This antibody is tested and proven to work in the following applications:

Thrombin Receptor Antibody
33500-100ul 100ul
EUR 252

Thrombin Receptor Antibody
33500-50ul 50ul
EUR 187

Thrombin III Antibody
20-abx121017
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Thrombin III Antibody
abx023271-10ml 10 ml
EUR 411

Thrombin III Antibody
abx023272-1ml 1 ml
EUR 565

Thrombin Receptor Antibody
ABF0263 100 ug
EUR 438

Thrombin Receptor Antibody
AF0263 200ul
EUR 304
Description: Thrombin Receptor antibody detects endogenous levels of total Thrombin Receptor.

Thrombin antibody (HRP)
60R-1045 200 ug
EUR 418
Description: Sheep polyclonal Thrombin antibody (HRP) conjugated

Thrombin antibody (FITC)
60R-1046 100 ug
EUR 418
Description: Sheep polyclonal Thrombin antibody (FITC) conjugated

Thrombin antibody (biotin)
60R-1047 100 ug
EUR 418
Description: Sheep polyclonal Thrombin antibody (biotin) conjugated

Thrombin antibody (HRP)
60R-1048 200 ug
EUR 448
Description: Sheep polyclonal Thrombin antibody (HRP) conjugated

Thrombin antibody (HRP)
60R-1078 200 ug
EUR 445
Description: Sheep polyclonal Thrombin antibody (HRP) conjugated

Thrombin Receptor antibody
70R-30775 100 ug
EUR 327
Description: Rabbit polyclonal Thrombin Receptor antibody

Mouse Thrombin-Antithrombin (TAT) Complex AssayMax ELISA Kit
EMT1020-1 96 Well Plate
EUR 417

Human Thrombin-Antithrombin Complex (TAT) AssayMax ELISA Kit
ET1020-1 96 Well Plate
EUR 417

Human Trypsinogen Activation Peptide (TAP) Peptide (BSA)
20-abx651098
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Trypsinogen Activation Peptide (TAP) Peptide (OVA)
20-abx651099
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Trypsinogen Activation Peptide (TAP) Peptide (BSA)
20-abx651100
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Trypsinogen Activation Peptide (TAP) Peptide (OVA)
20-abx651101
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Trypsinogen Activation Peptide (TAP) Peptide (BSA)
20-abx651102
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Trypsinogen Activation Peptide (TAP) Peptide (OVA)
20-abx651103
  • EUR 258.00
  • EUR 189.00
  • EUR 537.00
  • EUR 272.00
  • EUR 217.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human IgG Fab fragment, purified
20007-1-FAB 1 mg
EUR 202

Human IgG (Fc) fragment, purified
20007-1-FC 0.5 mg
EUR 208

Mouse IgG Fab fragment, purified
20008-1-FAB 1 mg
EUR 164

Mouse IgG (Fc) fragment, purified
20008-1-FC 0.5 mg
EUR 250

Rabbit IgG Fab fragment, purified
20009-1-FAB 1 mg
EUR 202

Rabbit IgG (Fc) fragment, purified
20009-1-FC 0.5 mg
EUR 250

Goat IgG Fab fragment, purified
20011-1-FAB 0.5 mg
EUR 202

Goat IgG (Fc) fragment, purified
20011-1-FC 0.5 mg
EUR 250

Trypsinogen Activation Peptide (TAP) Polyclonal Antibody (Human)
4-PAA634Hu01
  • EUR 232.00
  • EUR 2285.00
  • EUR 574.00
  • EUR 289.00
  • EUR 208.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human Trypsinogen Activation Peptide (TAP)

heparin cofactor II precursor fragment [Homo sapiens]
A1144-1 1 mg
EUR 108
Description: heparin cofactor II precursor fragment [Homo sapiens], (C65H99N17O18), a peptide with the sequence H2N-Tyr-Glu-Ile-Thr-Thr-Ile-His-Asn-Leu-Phe-Arg-OH, MW=1406.58.

alpha-1 antitrypsin fragment 235-243 [Homo sapiens]/[Papio hamadryas]/[Cercopithecus aethiops]
A1052-1 1 mg
EUR 108
Description: alpha-1 antitrypsin fragment 235-243 [Homo sapiens]/[Papio hamadryas]/[Cercopithecus aethiops]

Morphine Modulating Peptide, C-Terminal Fragment
5-01561 4 x 5mg Ask for price

HIV-gp120-Fragment (318-327) Peptide
20-abx266178
  • EUR 439.00
  • EUR 718.00
  • EUR 328.00
  • 10 mg
  • 25 mg
  • 5 mg

Morphine Modulating Peptide, C-Terminal Fragment
20-abx265838
  • EUR 356.00
  • EUR 537.00
  • EUR 286.00
  • 10 mg
  • 25 mg
  • 5 mg

This on-line, cross-sectional examine aimed to find out the affect of COVID-19 on perceived stress ranges of medical students, examine doable contributing and assuaging elements, and produce suggestions for medical faculties to implement throughout future healthcare emergencies. The majority (54.5%) of respondents reported ranges of stress starting from reasonable to excessive.

Les controles de qPCR pour le Covid

Envoi de Paris

  1. NATtrol Influenza/RSV Negative Control (6 x 0.5 mL) NATCXVA9-6C
  2. NATtrol Influenza Verification Panel (18 x 0.5 mL) NATFVP(XP)-C
  3. NATtrol Influenza A/B Positive Control (6 x 0.5 mL) NATFLUA/B-6MC
  4. NATtrol Influenza Negative Control (6 x 0.5 mL) NATCXVA9-6MC
  5. NATtrol Influenza A H1N1 Positive Control (6 x 0.5 mL) NATFLUAH1N1-6MC
  6. NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) NATFRC-6C
  7. NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) NATCV9-6C

The effects of long-term extracurricular scientific research on the medical students: Insight from Jinan University Medical School

The advantages and long-term effects of extracurricular scientific research on undergraduate college students in lots of international locations have been intensively investigated, but it surely stays obscure for Chinese medical college students. In this examine, we investigated the end result of 60 medical college students who’ve participated in extracurricular scientific research at Jinan University Medical School over a interval of 7 years (2011-2018). The outcomes revealed that these college students have contributed to 31 biomedical science articles in respected educational journals, as first- or co-authors.

Furthermore, additionally they independently procured numerous funding based mostly on their research achievements, and smaller awards for achievements in conferences and competitions. Assessment of the grade level common rating of these college students revealed that conducting extracurricular scientific research didn’t have an effect on their routine medical examine and examination grades (P>0.05). The college students benefited from collaborating in extracurricular research, by buying the potential to assume scientifically and enhancing their communication abilities.

In addition, the medical college students had been motivated to enlist for postgraduate research in order that they might additional embark in scientific research. In sum, Chinese medical college students are succesful of collaborating in scientific research and make a big contribution to science. Linear regressions had been adjusted for gender, anticipated specialty alternative, parental schooling, dwelling standing, monetary insecurity, randomization group and baseline JSE-S.

This examine was performed between February and March 2019, in the Eastern area of Saudi Arabia, utilizing scientific pharmacy college students at the two universities that supply a pharmacy program there (King Faisal University and Imam Abdulrahman bin Faisal University). An digital questionnaire instrument was tailored to discover the intentions of and boundaries to hold out medical research amongst the college students.

 Descriptive statistics are introduced as frequencies and percentages. A χ2 check was used to discover any statistically vital distinction between the pupil demographics and the intentions and boundaries relating to medical research. P ≤ 0.05 was thought-about statistically vital. Our examine highlights that the intention amongst scientific pharmacy college students to hold out medical research was poor. Educational establishments are suggested to offer extra monetary and logistic assist to their medical researchers.

Knowledge and attitudes of U.S. medical college students relating to the care of Asian American sufferers: a cross-sectional survey examine

Asian Americans (AsAm) are a quickly rising inhabitants in the U.S. With this rising inhabitants, U.S. healthcare suppliers have to be outfitted to offer culturally competent look after AsAm sufferers. This challenge surveyed U.S. medical college students on their information of and attitudes in the direction of AsAm to evaluate predictors of readiness to look after AsAm sufferers.
This cross-sectional examine surveyed medical college students who had accomplished at the least one scientific rotation. The survey was distributed on-line to 9 medical faculties all through the U.S. The survey measured self-rated information of, consolation with, cultural competency (CC) in the direction of, and specific biases in the direction of AsAm sufferers. The first three domains had been analyzed in a multivariate regression mannequin together with sociodemographic traits and previous scientific, curricular, and social experiences with AsAm. Explicit bias questions had been reported descriptively.
 There had been 688 respondents. Asian race, AsAm-prevalent hometown, AsAm-related extracurricular actions, Asian language information, and having taken a inhabitants well being course predicted elevated AsAm information. Social interactions with AsAm elevated consolation with AsAm sufferers. Increasing 12 months in medical college, extra frequent publicity to AsAm sufferers on rotations, and prior journey to an Asian nation had been predictors of elevated CC towards AsAm.
Importantly, having accomplished a CC course was a big predictor in all domains. In phrases of specific bias, college students felt that AsAm sufferers had been extra compliant than Caucasian sufferers. Students additionally believed that Caucasian sufferers had been usually extra prone to obtain self-perceived “most popular” versus “acceptable” care, however that in their very own scientific experiences neither group acquired most popular care.
Experience with and publicity to AsAm previous to and through medical college and CC programs might improve medical pupil information, consolation, and CC with AsAm sufferers. Standardized and longitudinal CC coaching, elevated simulations with AsAm sufferers, numerous pupil recruitment, and assist for college kids to have interaction in AsAm-related actions and work together with AsAm might enhance CC of future physicians in the direction of AsAm sufferers and presumably different minority populations.
The effects of long-term extracurricular scientific research on the medical students: Insight from Jinan University Medical School

Personality traits are related to cognitive empathy in medical college students however not with its evolution and interventions to enhance it

Cognitive empathy would possibly lower throughout medical college. Factors related to its evolution stay poorly understood, in addition to whether or not such components might average the impact of an intervention to protect cognitive empathy. The intention was to discover the associations between character traits and each cognitive empathy at baseline and its adjustments at follow-up. The attainable impact of an intervention depended upon character traits was additionally examined.
The cohort consisted of fourth 12 months medical college students and the associations between character traits, utilizing the Short Big Five Inventory, and cognitive empathy adjustments at 3-month, utilizing the Jefferson Scale of Empathy-Student model (JSE-S), had been examined. A randomization in two teams (Balint teams versus no intervention) allowed analyzing whether or not the impact of the intervention depended upon character traits.

[Sar1,Gly8]-Angiotensin II Peptide
20-abx266581
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

[Sar1,Ala8]-Angiotensin II Peptide
20-abx266583
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

[Sar1,Ile4,8]-Angiotensin II Peptide
20-abx266584
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

[Sar1,Thr8]-Angiotensin II Peptide
20-abx266585
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

Angiotensin II [Sar1 Ile8] Peptide
20-abx266588
  • EUR 718.00
  • EUR 328.00
  • EUR 467.00
  • 100 mg
  • 25 mg
  • 50 mg

Angiotensin II (4-8) Peptide
20-abx265182
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin II (3-8) Peptide
20-abx265183
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin II (1-4) Peptide
20-abx265185
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

[Asn1,Val5]-Angiotensin II Peptide
20-abx266003
  • EUR 384.00
  • EUR 592.00
  • EUR 300.00
  • 10 mg
  • 25 mg
  • 5 mg

Positive control tissue section for each antibody; Based on availability INQUIRE
Control-Slides Set of 5
EUR 176

Angiotensin II
A1042-10 10 mg
EUR 108
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung.

Angiotensin II
A1042-25 25 mg
EUR 131
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung.

Angiotensin II
A1042-250 250 mg
EUR 630
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung.

Angiotensin II
A1042-5 5 mg
EUR 84
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung.

Angiotensin II
H-1705.0025 25.0mg
EUR 176
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net

Angiotensin II
H-1705.0100 100.0mg
EUR 466
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net

Angiotensin II
H-7714.0005 5.0mg
EUR 60
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net

Angiotensin II
4917-5MG
EUR 202

[Sar1,Val5,Ala8]-Angiotensin II Peptide
20-abx266582
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

Angiotensin I / II (5-8) Peptide
20-abx265760
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin I / II (3-7) Peptide
20-abx265779
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin I / II (1-6) Peptide
20-abx265799
  • EUR 328.00
  • EUR 495.00
  • EUR 272.00
  • 10 mg
  • 25 mg
  • 5 mg

Human Drug Detoxication II
HDTX-II 1 set
EUR 645

Human Kinase Library II
HKIN-II 1 set
EUR 450

Human Cytokine Primer Library II
HCA-II 1 set
EUR 450

Rat Cytokine Primer Library II
RCA-II 1 set
EUR 548

Mouse Cytokine Primer Library II
MCA-II 1 set
EUR 450

AT1A, Angiotensin II receptor, (225 237) Peptide
20-abx266391
  • EUR 523.00
  • EUR 871.00
  • EUR 384.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin I / II (1-7) (Biotin) Peptide
20-abx266007
  • EUR 384.00
  • EUR 592.00
  • EUR 300.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin II Type 1 Receptor Blocking Peptide
DF7592-BP 1mg
EUR 195

Human Deoxyribonuclease II (Dnase II) Control/blocking peptide # 1
DNASE21-P 100 ug
EUR 164

Mouse Deoxyribonuclease II (Dnase II) Control/blocking peptide # 2
DNASE22-P 100 ug
EUR 164

Human Colon Cancer Primer Library II
HCCP-II 1 set
EUR 548

Human DNA Repair Primer Library II
HDRL-II 1 set
EUR 548

Mouse DNA Repair Primer Library II
MDRL-II 1 set
EUR 645

Angiotensin II human
HY-13948 50mg
EUR 394

[Sar1] Angiotensin II
5-00293 24 x 5mg Ask for price

Angiotensin II Antipeptide
5-00686 4 x 5mg Ask for price

Angiotensin II human
5-00687 4 x 5mg Ask for price

Angiotensin II Substrate
5-00693 4 x 5mg Ask for price

Angiotensin II Antipeptide
20-abx265974
  • EUR 384.00
  • EUR 592.00
  • EUR 300.00
  • 10 mg
  • 25 mg
  • 5 mg

(Sar1)-Angiotensin II
H-1740.0025 25.0mg
EUR 273
Description: Sum Formula: C49H71N13O10; CAS# [51833-69-3]

(Sar1)-Angiotensin II
H-1740.0100 100.0mg
EUR 756
Description: Sum Formula: C49H71N13O10; CAS# [51833-69-3]

(Val5)-Angiotensin II
H-1750.0025 25.0mg
EUR 273
Description: Sum Formula: C49H69N13O12; CAS# [58-49-1]

(Val5)-Angiotensin II
H-1750.0100 100.0mg
EUR 756
Description: Sum Formula: C49H69N13O12; CAS# [58-49-1]

Angiotensin II Antipeptide
H-8160.0005 5.0mg
EUR 273
Description: Sum Formula: C42H62N10O12; CAS# [121379-63-3]

Angiotensin II Antipeptide
H-8160.0025 25.0mg
EUR 998
Description: Sum Formula: C42H62N10O12; CAS# [121379-63-3]

Angiotensin II antibody
70-1089 100 ug
EUR 727
Description: Rabbit anti-human Angiotensin II antibody

Angiotensin II protein
30R-2769 5 mg
EUR 247
Description: Purified native Human Angiotensin II protein

Angiotensin II (Ang II) Antibody
20-abx131719
  • EUR 314.00
  • EUR 759.00
  • EUR 398.00
  • EUR 154.00
  • EUR 244.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Angiotensin II (Ang II) Antibody
20-abx130645
  • EUR 300.00
  • EUR 133.00
  • EUR 759.00
  • EUR 398.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Angiotensin II (Ang II) Antibody
20-abx101258
  • EUR 300.00
  • EUR 133.00
  • EUR 759.00
  • EUR 398.00
  • EUR 258.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Angiotensin II (Ang II) Antibody
abx021123-02mg 0.2 mg
EUR 1135

Human Cancer Driver Gene II Primer Library
HCDG-II 1 set
EUR 645

Human Interferon Type II Signaling Primer Library
HIFN-II 1 set
EUR 548

Angiotensin Peptide
20-abx265534
  • EUR 356.00
  • EUR 537.00
  • EUR 286.00
  • 10 mg
  • 25 mg
  • 5 mg

[Sar1]-Angiotensin I / II (1-7) amide Peptide
20-abx266580
  • EUR 523.00
  • EUR 286.00
  • EUR 370.00
  • 100 mg
  • 25 mg
  • 50 mg

Angiotensin II (Ang II) ELISA Kit
abx511338-96tests 96 tests
EUR 668

Angiotensin II 5-valine
HY-P0108 50mg
EUR 153

[Sar1, Ile8]-Angiotensin II
HY-P1564 50mg
EUR 497

[Asn1, Val5]-Angiotensin II
5-00053 4 x 5mg Ask for price

[Sar1, Ala8]-Angiotensin II
5-00294 24 x 5mg Ask for price

[Sar1, Gly8]-Angiotensin II
5-00295 24 x 5mg Ask for price

[Sar1, Thr8]-Angiotensin II
5-00297 24 x 5mg Ask for price

[Val5] Angiotensin II, human
5-00373 4 x 5mg Ask for price

Angiotensin II [Sar1 Ile8]
5-00691 24 x 5mg Ask for price

Angiotensin II (AngII) Antibody
20-abx175396
  • EUR 411.00
  • EUR 133.00
  • EUR 1135.00
  • EUR 551.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Synthetic Angiotensin II (AngII)
4-SPA005Mi01
  • EUR 350.88
  • EUR 197.00
  • EUR 1040.80
  • EUR 413.60
  • EUR 727.20
  • EUR 298.00
  • EUR 2452.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human, Mouse, Rat Angiotensin II expressed in: E.coli

[Sar1,Ala8]-Angiotensin II
SP-100367-25 25 mg
EUR 286

[Sar1,Gly8]-Angiotensin II
SP-100368-25 25 mg
EUR 286

[Sar1,Thr8]-Angiotensin II
SP-100369-25 25 mg
EUR 286

(Sar1,Gly8)-Angiotensin II
H-1725.0025 25.0mg
EUR 273
Description: Sum Formula: C42H65N13O10; CAS# [51887-62-8]

(Sar1,Gly8)-Angiotensin II
H-1725.0100 100.0mg
EUR 756
Description: Sum Formula: C42H65N13O10; CAS# [51887-62-8]

(Sar1,Ile8)-Angiotensin II
H-1730.0025 25.0mg
EUR 273
Description: Sum Formula: C46H73N13O10; CAS# [37827-06-8]

(Sar1,Ile8)-Angiotensin II
H-1730.0100 100.0mg
EUR 756
Description: Sum Formula: C46H73N13O10; CAS# [37827-06-8]

(Sar1,Thr8)-Angiotensin II
H-1745.0025 25.0mg
EUR 273
Description: Sum Formula: C44H69N13O11; CAS# [53632-49-8]

(Sar1,Thr8)-Angiotensin II
H-1745.0100 100.0mg
EUR 756
Description: Sum Formula: C44H69N13O11; CAS# [53632-49-8]

(Asn1,Val5)-Angiotensin II
H-6010.0025 25.0mg
EUR 321
Description: Sum Formula: C49H70N14O11; CAS# [53-73-6]

(Asn1,Val5)-Angiotensin II
H-6010.0100 100.0mg
EUR 902
Description: Sum Formula: C49H70N14O11; CAS# [53-73-6]

Angiotensin II Receptor Ligand
H-9395.0001 1.0mg
EUR 176
Description: Sum Formula: C52H69N13O11; CAS# [127060-75-7]

Angiotensin II Receptor Ligand
H-9395.0005 5.0mg
EUR 611
Description: Sum Formula: C52H69N13O11; CAS# [127060-75-7]

Anti-Angiotensin II Antibody
A1588-100
EUR 338

Anti-Angiotensin II Antibody
A1588-30T
EUR 146

Mouse Hexokinase 2 (HXK-II) Control/blocking peptide
HXK23-P 100 ug
EUR 164

Mouse Angiotensin converting enzyme 1 (ACE-1) control peptide # 1
ACE11-P 100 ug
EUR 164

Human Angiotensin converting enzyme 1 (ACE-1) control peptide # 2
ACE12-P 100 ug
EUR 164

Mouse Angiotensin converting enzyme 2 (ACE-2) control peptide # 1
ACE21-P 100 ug
EUR 164

Human Angiotensin converting enzyme 2 (ACE-2) control peptide # 2
ACE22-P 100 ug
EUR 164

Angiotensin I Peptide
20-abx265095
  • EUR 439.00
  • EUR 495.00
  • EUR 718.00
  • EUR 1247.00
  • EUR 328.00
  • 10 mg
  • 20 mg
  • 25 mg
  • 50 mg
  • 5 mg

Angiotensin III Peptide
20-abx265119
  • EUR 356.00
  • EUR 537.00
  • EUR 286.00
  • 10 mg
  • 25 mg
  • 5 mg

Angiotensin A Peptide
20-abx266011
  • EUR 384.00
  • EUR 592.00
  • EUR 300.00
  • 10 mg
  • 25 mg
  • 5 mg

Mouse Angiotensin II (Ang II) ELISA Kit
20-abx153637
  • EUR 6642.00
  • EUR 3542.00
  • EUR 825.00
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Rat Angiotensin II (Ang II) ELISA Kit
abx575126-96tests 96 tests
EUR 668

Mouse Angiotensin II (Ang II) ELISA Kit
abx575127-96tests 96 tests
EUR 786
The cohort included 311 members from October 2015 to December 2016 at Paris Diderot and Paris Descartes University. At follow-up, there was a JSE-S whole rating improve of 1.22(SD:9.10) in the intervention group, in comparison with a lower of 1.64(SD:10.74) in the different group. Baseline JSE-S was positively related to Extraversion and Conscientiousness and negatively with Neuroticism. In distinction, we discovered no associations between baseline character traits and JSE-S change. There had been no interactions between character traits and randomization group.